<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="0d02b3a0-4de3-473b-8ed9-a1974747970f" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title ID="INV-8b7012c8-6612-4a58-8b60-b9dada6271ba" mediaType="text/x-hl7-title+xml">8% Hepatasol<content styleCode="bold"><sup>&#174;</sup></content> (Amino Acid) Injection<br />Protect from light until use.</title>
<effectiveTime value="20060613" />
<setId root="0d02b3a0-4de3-473b-8ed9-a1974747970f" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>Baxter Healthcare Corporation</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="AFE2F6A2-6158-79CD-41F0-5FAEB5A55E79" />
<effectiveTime value="20060613" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0338-0497" codeSystem="2.16.840.1.113883.6.69" />
<name>Hepatasol</name>
<formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION" />
<activeIngredient>
<quantity>
<numerator unit="g" value="1.10">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="1.10" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="GMW67QNF9C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Leucine</name>
<activeMoiety>
<activeMoiety>
<code code="GMW67QNF9C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Leucine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.90">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.90" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="04Y7590D77" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Isoleucine</name>
<activeMoiety>
<activeMoiety>
<code code="04Y7590D77" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Isoleucine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.84">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.84" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="HG18B9YRS7" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Valine</name>
<activeMoiety>
<activeMoiety>
<code code="HG18B9YRS7" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Valine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.61">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.61" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="K3Z4F929H6" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Lysine</name>
<activeMoiety>
<activeMoiety>
<code code="K3Z4F929H6" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Lysine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.45">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.45" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="2ZD004190S" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Threonine</name>
<activeMoiety>
<activeMoiety>
<code code="2ZD004190S" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Threonine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.10">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.10" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Methionine</name>
<activeMoiety>
<activeMoiety>
<code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Methionine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.10">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.10" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="47E5O17Y3R" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Phenylalanine</name>
<activeMoiety>
<activeMoiety>
<code code="47E5O17Y3R" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Phenylalanine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.066">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.066" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="8DUH1N11BX" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Tryptophan</name>
<activeMoiety>
<activeMoiety>
<code code="8DUH1N11BX" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Tryptophan</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.90">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.90" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="TE7660XO1C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Glycine</name>
<activeMoiety>
<activeMoiety>
<code code="TE7660XO1C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Glycine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.80">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.80" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="9DLQ4CIU6V" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Proline</name>
<activeMoiety>
<activeMoiety>
<code code="9DLQ4CIU6V" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Proline</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.77">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.77" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="OF5P57N2ZX" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Alanine</name>
<activeMoiety>
<activeMoiety>
<code code="OF5P57N2ZX" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Alanine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.60">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.60" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="94ZLA3W45F" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Arginine</name>
<activeMoiety>
<activeMoiety>
<code code="94ZLA3W45F" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Arginine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.50">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.50" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="452VLY9402" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Serine</name>
<activeMoiety>
<activeMoiety>
<code code="452VLY9402" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Serine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.24">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.24" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Histidine</name>
<activeMoiety>
<activeMoiety>
<code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Histidine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="0.020">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.020" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="ZT934N0X4W" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Cysteine Hydrochloride</name>
<activeMoiety>
<activeMoiety>
<code code="K848JZ4886" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Cysteine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>Leucine, Isoleucine, Valine, Lysine, Threonine, Methionine, Phenylalanine, Tryptophan, Glycine, Proline, Alanine, Arginine, Serine, Histidine and Cysteine</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<quantity>
<numerator unit="g" value="0.115">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.115" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<inactiveIngredientSubstance>
<code code="E4GA8884NN" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Phosphoric Acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>Glacial Aceic Acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<quantity>
<numerator unit="g" value="0.1">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="0.1" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<inactiveIngredientSubstance>
<name>Sodium Bisulphite</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator unit="mL" value="500">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="500" />
</numerator>
<denominator value="0">
<translation codeSystem="2.16.840.1.113883.3.26.1.1" value="0" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0338-0497-03" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section ID="INV-7eaac63d-0da9-4882-b6fe-c54b5f311e12">
<id root="7B2A3861-0D11-6B96-C260-86431FA7B23C" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION" />
<title ID="INV-9e8b1385-e7a8-4b73-847c-927eb9802aa0" mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text ID="INV-b7bed2c3-b4c7-4a19-86f7-688140f298a1"><paragraph ID="INV-c2a29e42-3745-4719-bd01-a2db1f814eb6">8%
                            Hepatasol<sup>&#174;</sup> (Amino Acid) Injection is a sterile, nonpyrogenic,
                            hypertonic solution containing crystalline amino acids.</paragraph><paragraph ID="INV-540423cc-f0d1-4d3b-a02d-04731a1fa5e8">Each 100 mL
                            contains:</paragraph><table frame="void"><col align="left" width="400pt" />
<col align="left" width="200pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle">
                                        Amino Acids </td><td align="right" valign="middle"> 8g </td></tr>
<tr valign="top"><td align="left" valign="middle"> Total
                                        Nitrogen </td><td align="right" valign="middle"> 1.22g </td></tr>
</tbody>
</table><paragraph ID="INV-1c954101-5132-4d4d-a4c0-9fb86bacc4fc"><content styleCode="bold">Essential Amino Acids</content></paragraph><table frame="void"><col align="left" width="400pt" />
<col align="left" width="200pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle">Leucine &#8211; (CH<sub>3</sub>)<sub>2</sub> CHCH<sub>2</sub>CH
                                            (NH<sub>2</sub>) COOH</td><td align="right" valign="middle"> 1.10g</td></tr>
<tr valign="top"><td align="left" valign="middle">Isoleucine &#8211; CH<sub>3</sub>CH<sub>2</sub>CH
                                        (CH<sub>3</sub>) CH (NH<sub>2</sub>) COOH</td><td align="right" valign="middle"> 0.90g</td></tr>
<tr valign="top"><td align="left" valign="middle">Valine &#8211; (CH<sub>3</sub>)<sub>2</sub>CHCH (NH<sub>2</sub>)
                                        COOH</td><td align="right" valign="middle"> 0.84g</td></tr>
<tr valign="top"><td align="left" valign="middle">Lysine &#8211; (added as lysine acetate) H<sub>2</sub>N
                                            (CH<sub>2</sub>)<sub>4</sub>CH (NH<sub>2</sub>) COOH</td><td align="right" valign="middle"> 0.61g</td></tr>
<tr valign="top"><td align="left" valign="middle">Threonine &#8211; CH<sub>3</sub>CH (OH) CH (NH<sub>2</sub>) COOH</td><td align="right" valign="middle"> 0.45g</td></tr>
<tr valign="top"><td align="left" valign="middle">Methionine &#8211; CH<sub>3</sub>S (CH<sub>2</sub>)<sub>2</sub>CH
                                            (NH<sub>2</sub>) COOH</td><td align="right" valign="middle"> 0.10g</td></tr>
<tr valign="top"><td align="left" valign="middle">Phenylalanine &#8211; (C<sub>6</sub>H<sub>5</sub>)
                                        CH<sub>2</sub>CH (NH<sub>2</sub>) COOH</td><td align="right" valign="middle"> 0.10g</td></tr>
<tr valign="top"><td align="left" valign="middle">Tryptophan &#8211;
                                            (C<sub>8</sub>H<sub>6</sub>N) CH<sub>2</sub>CH
                                        (NH<sub>2</sub>) COOH</td><td align="right" valign="middle"> 0.066g </td></tr>
</tbody>
</table><paragraph ID="INV-80298cbe-c3af-45ec-9f03-1fcfafeae1fb"><content styleCode="bold">Nonessential Amino Acids</content></paragraph><table><col align="left" width="400pt" />
<col align="left" width="200pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle">Glycine &#8211; H<sub>2</sub>NCH<sub>2</sub>COOH</td><td align="right" valign="middle">
                                        0.90g </td></tr>
<tr valign="top"><td align="left" valign="middle">Proline &#8211; [(CH<sub>2</sub>)<sub>3</sub> NH CH] COOH</td><td align="right" valign="middle">
                                        0.80g </td></tr>
<tr valign="top"><td align="left" valign="middle">Alanine &#8211; CH<sub>3</sub>CH (NH<sub>2</sub>) COOH</td><td align="right" valign="middle">
                                        0.77g </td></tr>
<tr valign="top"><td align="left" valign="middle">Arginine &#8211; H<sub>2</sub>NC (NH) NH
                                        (CH<sub>2</sub>)<sub>3</sub>CH (NH<sub>2</sub>) COOH</td><td align="right" valign="middle">
                                        0.60g </td></tr>
<tr valign="top"><td align="left" valign="middle">Serine &#8211; HOCH<sub>2</sub>CH (NH<sub>2</sub>) COOH</td><td align="right" valign="middle">
                                        0.50g </td></tr>
<tr valign="top"><td align="left" valign="middle">Histidine &#8211; (C<sub>3</sub>H<sub>3</sub>N<sub>2</sub>)
                                            CH<sub>2</sub>CH (NH<sub>2</sub>) COOH</td><td align="right" valign="middle">
                                        0.24g </td></tr>
<tr valign="top"><td align="left" valign="middle">Cysteine Hydrochloride &#8211;
                                        [SHCH<sub>2</sub>CHNH<sub>2</sub>COOH]&#8226; HCl &#8226;
                                        H<sub>2</sub>0</td><td align="right" valign="middle">
                                        Less than 0.020g </td></tr>
<tr valign="top"><td align="left" valign="middle"> Phosphoric Acid NF </td><td align="right" valign="middle">
                                        0.115g </td></tr>
<tr valign="top"><td align="left" valign="middle"> pH (pH adjusted with glacial acetic acid) </td><td align="right" valign="middle"> 6.5
                                        (6.0 to 6.8) </td></tr>
</tbody>
</table><paragraph ID="INV-d08d824a-bdfd-4932-959c-05b6f9ad499f"><content styleCode="bold">Electrolyte profile mEq per liter*</content></paragraph><paragraph ID="INV-c622b60d-60c8-4005-9ce7-7fbfce79d19b">Sodium 10, Chloride
                            less than 3, Phosphate (as HPO<sub>4</sub>=) 20 (10 mmoles/Liter),
                            Acetate 63 (provided as glacial acetic acid and lysine acetate).</paragraph><paragraph ID="INV-4c6736a5-879f-4244-85b1-c2726287411d">0.1 g/100 mL (10
                            mEq/L) sodium bisulfite added as stabilizer.</paragraph><paragraph ID="INV-7b7f0f74-ded0-4583-b974-369d1bb78a4e"><sub>*Balanced by ions from amino acids.</sub></paragraph><table frame="void"><col align="left" width="400pt" />
<col align="left" width="200pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle"><content styleCode="bold">Osmolarity (Calc.)</content></td><td align="right" valign="middle"><content styleCode="bold">785 m0smol/L</content></td></tr>
</tbody>
</table></text>
<effectiveTime value="20060613" />
</section>
</component>
<component>
<section ID="INV-d8ff83e1-07f1-43e1-84a3-2a6d8f7d4126">
<id root="F1D61A5F-E294-2448-4357-80B5DF55EC78" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY SECTION" />
<title ID="INV-1890d560-308d-4972-ac8f-7db0a7a4624c" mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text ID="INV-e3369c53-aba8-4b06-9cc1-427689d348fe"><paragraph ID="INV-583d84b0-fa02-4c35-bed3-cfc1a0a5d770">8%
                            Hepatasol<sup>&#174;</sup> (Amino Acid) Injection provides a mixture of
                            essential and nonessential amino acids with high concentrations of the
                            branched chain amino acids isoleucine, leucine, and valine, and low
                            concentrations of methionine and the aromatic amino acids phenylalanine
                            and tryptophan, relative to general purpose amino acid injections, This
                            amino acid composition has been specifically formulated to provide a
                            well tolerated nitrogen source for nutritional support and therapy of
                            patients with liver disease who have hepatic encephalopathy.</paragraph><paragraph ID="INV-49c95951-3238-4c7c-a6fe-054a82d5f8e7">The precise
                            mechanisms which produce the therapeutic effects of this amino acid
                            formulation are not known. The etiopathology of hepatic encephalopathy
                            is also unknown and is thought to be of multifactorial origin. The
                            rationale for this amino acid formulation is based on observations of
                            plasma amino acid imbalances in patients with liver disease and on
                            theories which postulate that these abnormal patterns are causally
                            related to the development of hepatic encephalopathy.</paragraph><paragraph ID="INV-8a109332-b45f-4eca-9db4-3b9bc0c379cc">Clinical studies in
                            patients with hepatic encephalopathy showed that the infusion of this
                            amino acid formulation reversed the abnormal plasma amino acid pattern            characterized by decreased levels of branched chain amino acids and
                            elevated levels of aromatic amino acids and methionine. The trend toward
                            normalization of these amino acids was generally associated with an
                            improvement in mental status and EEG patterns. This clinical response
                            was observed in the majority of patients studied. Nitrogen balance was significantly improved and mortality reduced in these typically
                            protein-intolerant patients who received substantial amounts of protein
                            equivalent as this amino acid injection.</paragraph><paragraph ID="INV-1165535c-5429-43c0-8091-1031411d71e4">When infused with
                            hypertonic dextrose as a calorie source, supplemented with electrolytes,
                            vitamins, and minerals, this amino acid formulation provides total
                            parenteral nutrition in patients with liver disease, with the exception
                            of essential fatty acids.</paragraph><paragraph ID="INV-c9b308d7-bcdc-47cc-b24d-06d309c15f8d">Phosphate is a
                            major intracellular anion which participates in providing energy for
                            metabolism of substrates and contributes to significant metabolic and
                            enzymatic reactions in all organs and tissues. It exerts a modifying
                            influence on calcium levels, a buffering effect on acid-base
                            equilibrium, and has a primary role in the renal excretion of hydrogen
                            ions.</paragraph><paragraph ID="INV-56306b1e-ee69-4317-9f53-e1d166a54a0f">It is thought that
                            the acetate from lysine acetate and acetic acid, under the conditions of
                            parenteral nutrition, does not impact net acid-base balance when renal
                            and respiratory functions are normal. Clinical evidence seems to support
                            this thinking; however, confirmatory experimental evidence is not
                            available.</paragraph><paragraph ID="INV-adbe02da-6d2e-4514-a5ae-5daa29a160f2">The amounts of
                            sodium and chloride present are not of clinical
                        significance.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
<component>
<section ID="INV-3514be0c-2c84-4bc3-a23a-8b42e353e989">
<id root="2AE71E90-DADF-C157-98E1-9AAFF98F7A9D" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS AND USAGE SECTION" />
<title ID="INV-b2832624-8568-4656-afea-b8ac683c191f" mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text ID="INV-b2df40a7-5cea-4ef9-aed6-e468c5fbe14c"><paragraph ID="INV-aac138ae-15e5-40e6-99ff-544f5f0f3e68">8%
                            Hepatasol<sup>&#174;</sup> (Amino Acid) Injection is indicated for the
                            treatment of hepatic encephalopathy in patients with cirrhosis or
                            hepatitis. 8% Hepatasol<sup>&#174;</sup> (Amino Acid) Injection provides
                            nutritional support for patients with these diseases of the liver who
                            require parenteral nutrition and are intolerant of general purpose amino
                            acid injections, which are contraindicated in patients with hepatic
                            coma.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
<component>
<section ID="INV-7b72062b-6371-45b3-b1a5-abea35a7e1d8">
<id root="2B9245AF-6DD4-78B6-08E8-827C0DBFC669" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION" />
<title ID="INV-e60f6b15-f63e-48cd-8b31-5ba5de68d274" mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text ID="INV-dd852c13-c06c-4a6f-9c0d-cd88b07f2c24"><paragraph ID="INV-7c01fbe6-cb8d-4a30-8536-01551f98706b">8%
                            Hepatasol<sup>&#174;</sup> (Amino Acid) Injection is contraindicated in
                            patients with anuria, inborn errors of amino acid metabolism, especially
                            those involving branched chain amino acid metabolism such as Maple Syrup
                            Urine Disease and Isovaleric Acidemia, or hypersensitivity to one or
                            more amino acids present in the solution.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
<component>
<section ID="INV-04d7ff43-e545-4408-881f-f8e674c85bcf">
<id root="DFA8B78A-53EE-C5CB-5C31-43136658A26E" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS SECTION" />
<title ID="INV-b2bddb47-c4e7-4685-a33c-0a5f74fc4587" mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text ID="INV-dfd7fc50-be9a-4dfc-a1c1-d9ed4e2fa726"><paragraph ID="INV-ab3af372-c98f-4f4e-971e-3368c6c7be0e">Additives may be
                            incompatible. Consult with pharmacist, if available. When introducing
                            additives, use aseptic techniques. Mix thoroughly. Do not store.</paragraph><paragraph ID="INV-c69cbadd-b25c-461a-929e-c693f01875e3">Because of the
                            potential for life-threatening events, caution should be taken to ensure
                            that precipitates have not formed in any parenteral nutrient admixture.</paragraph><paragraph ID="INV-58553cae-0bd8-4f0e-bf45-2e9a6837c0db">This product
                            contains sodium bisulfite, a sulfite that may cause allergic-type
                            reactions including anaphylactic symptoms and life-threatening or less
                            severe asthmatic episodes in certain susceptible people. The overall
                            prevalence of sulfite sensitivity in the general population is unknown
                            and probably low. Sulfite sensitivity is seen more frequently in
                            asthmatic than in nonasthmatic people.</paragraph><paragraph ID="INV-a77f6708-237d-45f6-b57e-2fa89ba28236">Safe, effective use
                            of parenteral nutrition requires a knowledge of nutrition as well as
                            clinical expertise in recognition and treatment of the complications
                            which can occur. <content styleCode="bold">Frequent evaluations and
                                laboratory determinations are necessary for proper monitoring of
                                parenteral nutrition.</content> Studies should include blood sugar,
                            serum proteins, kidney and liver function tests, electrolytes, hemogram,
                            carbon dioxide content, serum osmolarities, blood cultures, and blood
                            ammonia levels.</paragraph><paragraph ID="INV-55e53927-3653-47fa-8411-4bef213add65">Administration of
                            amino acids in the presence of impaired renal function or
                            gastrointestinal bleeding may augment an already elevated blood urea
                            nitrogen. Patients with azotemia from any cause should not be infused
                            with amino acids without regard to total nitrogen intake.</paragraph><paragraph ID="INV-256194cb-1176-4f69-8156-01b2e0b3efd5">Administration of
                            intravenous solutions can cause fluid and/or solute overload resulting
                            in dilution of serum electrolyte concentrations, over-hydration,
                            congested states, or pulmonary edema. The risk of dilutional states is                   inversely proportional to the electrolyte concentrations of the
                            solutions. The risk of solute overload causing congested states with
                            peripheral and pulmonary edema is directly proportional to the
                            electrolyte concentrations of the solutions.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
<component>
<section ID="INV-2e419993-b01c-477f-809f-123d1b5461d1">
<id root="B65FC799-89C0-81C2-8BE4-3E9993BD272E" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS SECTION" />
<title ID="INV-eb4292ee-5a18-46c6-be3d-2862592f1853" mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<effectiveTime value="20060613" />
<component>
<section ID="INV-a8c00a8f-bddf-447c-8c32-426292f5725a">
<id root="50AD80A9-5621-2623-42AA-838408A74EA5" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GENERAL PRECAUTIONS SECTION" />
<title ID="INV-f517bf82-2537-4c78-9f29-861bf6def587" mediaType="text/x-hl7-title+xml">General</title>
<text ID="INV-f1497ff8-dd74-48cd-a2ab-62dd3cf9614f"><paragraph ID="INV-b32f6d9d-b3f7-42e2-a47c-d3b19ab49dcf">Clinical
                                    evaluation and periodic laboratory determinations are necessary
                                    to monitor changes in fluid balance, electrolyte concentrations,
                                    and acid-base balance during prolonged parenteral therapy or
                                    whenever the condition of the patient warrants such evaluation.
                                    Significant deviations from normal concentrations may require             the use of additional electrolyte supplements.</paragraph><paragraph ID="INV-2b079dd7-193c-42fc-8419-6bbae1c5562f">Strongly
                                    hypertonic nutrient solutions should be administered through an
                                    indwelling intravenous catheter with the tip located in the
                                    superior vena cava.</paragraph><paragraph ID="INV-2b13eb68-7e16-49a1-9919-3b123f0bf4d4">Special
                                    care must be taken when giving hypertonic dextrose to a diabetic
                                    or prediabetic patient. To prevent severe hyperglycemia in such
                                    patients, insulin may be required.</paragraph><paragraph ID="INV-0f0c9db3-9413-4ece-b76b-c08654624391">Peripheral
                                    intravenous administration of 8% Hepatasol<sup>&#174;</sup> (Amino
                                    Acid) Injection requires appropriate dilution and provision of
                                    adequate calories. Care should be taken to assure proper
                                    placement of the needle within the lumen of the vein. The
                                    venipuncture site should be inspected frequently for signs of
                                    infiltration. If venous thrombosis or phlebitis occurs,
                                    discontinue infusions or change infusion site and initiate
                                    appropriate treatment.</paragraph><paragraph ID="INV-b718492b-0873-48b5-9bad-1386fd52c33f">Care should
                                    be taken to avoid circulatory overload, particularly in patients
                                    with cardiac insufficiency.</paragraph><paragraph ID="INV-dd976628-c22b-4424-97e8-e69212d5f7b0">In patients
                                    with myocardial infarct, infusion of amino acids should always
                                    be accompanied by dextrose since in anoxia, free fatty acids
                                    cannot be utilized by the myocardium and energy must be produced
                                    anaerobically from glycogen or glucose.</paragraph><paragraph ID="INV-38d442f1-598d-4a77-8b5c-46bd0709cbeb">Infusion of
                                    this amino acid formulation may not affect the clinical course
                                    of patients with fulminant hepatitis who have a poor prognosis
                                    and are generally unresponsive to treatment. It has been shown
                                    that the abnormal plasma amino acid pattern in fulminant
                                    hepatitis differs from that in chronic liver disease.</paragraph><paragraph ID="INV-b034cdcb-3728-4eb9-b8e9-7a7f89a19e22">Extraordinary electrolyte losses such as may occur during
                                    protracted nasogastric suction, vomiting, diarrhea, or
                                    gastrointestinal fistula drainage may necessitate additional
                                    electrolyte supplementation.</paragraph><paragraph ID="INV-f8add7cb-4c24-452c-963c-301450a4feca">Administration of glucose at a rate exceeding the patient's
                                    utilization rate may lead to hyperglycemia, coma, and death.</paragraph><paragraph ID="INV-32e84ce6-d985-4bff-b9ff-af60f95881f2">Metabolic
                                    acidosis can be prevented or readily controlled by adding a
                                    portion of the cations in the electrolyte mixture as acetate                                salts and in the case of hyperchloremic acidosis, by keeping the
                                    total chloride content of the infusate to a minimum.</paragraph><paragraph ID="INV-6b14b461-b401-48d2-b2c8-ace57d63d88b">8%
                                        Hepatasol<sup>&#174;</sup> (Amino Acid) Injection contains less
                                    than 3 mEq chloride per liter.</paragraph><paragraph ID="INV-4f96a0b9-4e28-4a89-a0a3-90778c51837a">8%
                                        Hepatasol<sup>&#174;</sup> (Amino Acid) Injection contains 10
                                    mmoles/Liter of phosphate. Some patients, especially those with
                                    hypophosphatemia, may require additional phosphate. To prevent
                                    hypocalcemia, calcium supplementation should always accompany
                                    phosphate administration. To assure adequate intake, serum
                                    levels should be monitored frequently.</paragraph><paragraph ID="INV-929d8557-2af7-4bbd-9546-0808ed758180">8%
                                        Hepatasol<sup>&#174;</sup> (Amino Acid) Injection has not been
                                    adequately studied in pregnant women and children; therefore,
                                    its safe use in such patients has not been demonstrated.</paragraph><paragraph ID="INV-766a2323-761f-40f2-8bf9-b4bb934569e7">To minimize
                                    the risk of possible incompatibilities arising from mixing this
                                    solution with other additives that may be prescribed, the final
                                    infusate should be inspected for cloudiness or precipitation
                                    immediately after mixing, prior to administration, and                              periodically during administration.</paragraph><paragraph ID="INV-1009b9b5-627e-41e9-81de-647ee7d65c12">Use 8%
                                        Hepatasol<sup>&#174;</sup> (Amino Acid) Injection only if
                                    solution is clear, the seal unbroken, and vacuum is present.</paragraph><paragraph ID="INV-03589f44-28b6-40ad-9abb-00da70e42ea5">Carcinogenesis, mutagenesis, impairment of fertility: Studies
                                    with 8% Hepatasol<sup>&#174;</sup> (Amino Acid) have not been
                                    performed to evaluate carcinogenic potential, mutagenic          potential, or effects on fertility.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
<component>
<section ID="INV-286818c6-aef8-4c6e-91f6-9319b2b141fa">
<id root="98FEE890-6D24-4EBB-2E8D-5DCE4F074DD0" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY" />
<title ID="INV-b16a5078-9a9c-4fd7-8248-fe0adf85fb72" mediaType="text/x-hl7-title+xml">Usage in Pregnancy</title>
<effectiveTime value="20060613" />
<component>
<section ID="INV-a054c3f1-2e6a-4c3e-8a8c-de0bf6d422fd">
<id root="416123FB-DE6A-B893-AC0A-9B741BF1046A" />
<title ID="INV-d2affa97-758b-482d-86b5-e995a2c8b3b5" mediaType="text/x-hl7-title+xml">Pregnancy
                                        Category C.</title>
<text ID="INV-5bb4e076-7269-497d-9ada-1ff6260909b8"><paragraph ID="INV-056b6ed9-8f54-46f6-8bd1-c78e40e79896">Animal reproduction studies have not been conducted
                                            with 8% Hepatasol<sup>&#174;</sup> (Amino Acid) Injection. It
                                            is also not known whether 8% Hepatasol<sup>&#174;</sup>
                                            (Amino Acid) Injection can cause fetal harm when
                                            administered to a pregnant woman or can affect
                                            reproduction capacity. 8% Hepatasol<sup>&#174;</sup> (Amino
                                            Acid) Injection should be given to a pregnant woman only
                                            if clearly needed.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-a68e021a-7566-47e5-b42e-28d009c9c73c">
<id root="F382A225-A58B-5A70-8EAE-B5667BBFD80D" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NURSING MOTHERS SECTION" />
<title ID="INV-6bcc6355-8990-4869-8b9b-4e6f4f281706" mediaType="text/x-hl7-title+xml">Nursing Mothers:</title>
<text ID="INV-e57ddedb-5296-4c73-a5ad-d766c87de9ae"><paragraph ID="INV-745623ed-adc1-4b0b-b2fa-7a57492747f1">Caution
                                    should be exercised when 8% Hepatasol<sup>&#174;</sup> (Amino Acid)
                                    is administered to a nursing woman.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
<component>
<section ID="INV-bc7e8d99-1d9a-42e3-99f8-4a6137fab867">
<id root="E10FED14-D0FA-B5A2-6AE6-F50F6FB2E2C1" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE SECTION" />
<title ID="INV-17dd73c1-9198-4c64-bb8b-39201af2f8e3" mediaType="text/x-hl7-title+xml">Pediatric Use:</title>
<text ID="INV-7615dc11-2594-405b-8708-56a8c0768213"><paragraph ID="INV-4a90df8b-6f52-43f0-8488-a051c5abae02">Safety and
                                    effectiveness of 8% Hepatasol<sup>&#174;</sup> (Amino Acid) Injection
                                    in pediatric patients have not been established by adequate and
                                    well-controlled studies. However, the use of amino acid
                                    injections in pediatric patients as an adjunct in the offsetting
                                    of nitrogen loss or in the treatment of negative nitrogen
                                    balance is referenced in the medical literature. See <linkHtml ID="INV-d6787701-d26d-4727-8d16-95e0150cb9e3" href="#INV-78adea40-62df-4555-a138-f9e6e77405c7">DOSAGE AND
                                        ADMINISTRATION</linkHtml>.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
<component>
<section ID="INV-7d24fb31-8e4d-4e6d-bcb2-0328b6d22fe1">
<id root="535E8485-6065-F20C-A3D6-AC349E4E3831" />
<title ID="INV-e4e12e99-c9a4-462b-b90c-6b04613adf3b" mediaType="text/x-hl7-title+xml">Special Precautions
                                for Central Venous Nutrition</title>
<text ID="INV-ffcb546b-0acd-4e48-8999-d98bb7ff4be3"><paragraph ID="INV-0b8bc7c9-40f6-4b09-8b1c-82e05c55c481"><content styleCode="bold">Administration by central venous
                                        catheter should be used only by those familiar with this
                                        technique and its complications.</content></paragraph><paragraph ID="INV-763f1fd0-5784-4579-bc4f-058ed327f52c">Central
                                    venous nutrition may be associated with complications which can
                                    be prevented or minimized by careful attention to all aspects of
                                    the procedure, including solution preparation, administration,
                                    and patient monitoring. It is essential that a carefully
                                    prepared protocol, based on current medical practices, be
                                    followed, preferably by an experienced team.</paragraph><paragraph ID="INV-3def2cfa-70a8-46ea-928a-8cdf8cb7b1d4">Although a
                                    detailed discussion of the complications is beyond the scope of
                                    this insert, the following summary lists those based on current
                                    literature.</paragraph></text>
<effectiveTime value="20060613" />
<component>
<section ID="INV-7c2a7076-a5c4-4f83-b3e7-03886626b816">
<id root="D4F321CE-BB41-E809-2714-95C69514A413" />
<title ID="INV-d7275fe4-eea9-4a09-9601-22d285247982" mediaType="text/x-hl7-title+xml">Technical.</title>
<text ID="INV-9c707f2d-2af4-4dfe-8f6d-4cb42501b3ae"><paragraph ID="INV-944a4d02-7e14-4f0d-b89f-aa3f1b37bc95">The
                                            placement of a central venous catheter should be regarded as a surgical procedure. One should be fully                                            acquainted with various techniques of catheter insertion
                                            as well as recognition and treatment of complications.
                                            For details of techniques and placement sites, consult
                                            the medical literature. X-ray is the best means of
                                            verifying catheter placement. Complications known to
                                            occur from the placement of central venous catheters are
                                            pneumothorax, hemothorax, hydrothorax, artery puncture
                                            and transection, injury to the brachial plexus,
                                            malposition of the catheter, formation of arterio-venous
                                            fistula, phlebitis, thrombosis, pericardial tamponade,
                                            and air and catheter embolus.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
<component>
<section ID="INV-a021f433-ac13-45a3-be69-42dd49527feb">
<id root="C2C5C108-03FE-85C6-B74A-5B4280B1A6DE" />
<title ID="INV-89575f21-cec6-4438-a30b-825630679585" mediaType="text/x-hl7-title+xml">Septic.</title>
<text ID="INV-f118c3ac-1604-467f-969e-52d297baddb1"><paragraph ID="INV-2323ec7f-7960-4a75-ba56-cd8dee1f83b4">The
                                            constant risk of sepsis is present during total
                                            parenteral nutrition. Since contaminated solutions and
                                            infusion catheters are potential sources of infection,               it is imperative that the preparation of solutions and
                                            the placement and care of catheters be accomplished                                        under controlled aseptic conditions.</paragraph><paragraph ID="INV-08a2e58e-b91f-41ea-8639-4825087abab1">Solutions should ideally be prepared in the hospital
                                            pharmacy in a laminar flow hood. The key factor in their
                                            preparation is careful aseptic technique to avoid
                                            inadvertent touch contamination during mixing of
                                            solutions and subsequent admixtures.</paragraph><paragraph ID="INV-8ae75c57-771a-44ec-b498-d096f0473a06">Solutions should be used promptly after mixing. Any
                                            storage should be under refrigeration for as brief a
                                            time as possible. Administration time for a single
                                            bottle and set should never exceed 24 hours.</paragraph><paragraph ID="INV-cab6455f-7ec2-43c9-8693-5e300c172e5f">Consult the medical literature for a discussion of the
                                            management of sepsis. In brief, typical management
                                            includes replacing the solution being administered with
                                            a fresh container and set, and culturing the contents
                                            for bacterial or fungal contamination. If sepsis
                                            persists and another source of infection is not              identified, the catheter is removed, the proximal tip
                                            cultured, and a new catheter reinserted when the fever
                                            has subsided. Non-specific, prophylactic antibiotic
                                            treatment is not recommended.</paragraph><paragraph ID="INV-f3a331e0-026a-4cc6-9496-39b5b8dd923f">Clinical experience indicates that the catheter is
                                            likely to be the prime source of infection as opposed to
                                            aseptically prepared and properly stored
                                        solutions.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
<component>
<section ID="INV-68dceacf-bc21-4ff4-9217-81eabad152d6">
<id root="347A8C1E-295D-BB19-520B-2C3B4250E916" />
<title ID="INV-41dee3ad-2954-465e-8fb2-0fb1eba1de50" mediaType="text/x-hl7-title+xml">Metabolic.</title>
<text ID="INV-34d227a9-bb46-431d-a8b4-30ac2a0e90ae"><paragraph ID="INV-74fe6796-c24c-4087-a911-59daba9eacec">The
                                            following metabolic complications have been reported
                                            during the use of central venous nutrition: metabolic
                                            acidosis, hypophosphatemia, alkalosis, hyperglycemia and
                                            glycosuria, osmotic diuresis and dehydration, rebound
                                            hypoglycemia, elevated liver enzymes, hypo- and
                                            hyper-vitaminosis, electrolyte imbalances and                           hyperammonemia in children. Frequent clinical evaluation
                                            and laboratory determinations are necessary, especially
                                            during the first few days of therapy to prevent or
                                            minimize these complications.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section ID="INV-9c21f2fa-0814-420e-91fb-14dab7080dea">
<id root="F2BB45BE-155C-C635-A7EF-93FB21B487E6" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION" />
<title ID="INV-a8873d95-6bed-4de7-976d-101cb46a9c36" mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text ID="INV-720f0bb3-7271-4e4f-bb69-710f39257a8a"><paragraph ID="INV-ebe23f6b-12cc-43af-bd8f-696cf1b206c4">See <linkHtml ID="INV-5787d64e-4b53-4cc3-99aa-890a9ddd3b6a" href="#INV-ab3af372-c98f-4f4e-971e-3368c6c7be0e">WARNINGS</linkHtml>, and <linkHtml ID="INV-d9fae988-899f-4321-be76-6d1c3f560cbc" href="#INV-0b8bc7c9-40f6-4b09-8b1c-82e05c55c481">Special Precautions
                                for Central Venous Nutrition</linkHtml>.</paragraph><paragraph ID="INV-ddb1c2c4-9a04-41dd-8c57-57a02847a6e3">Reactions reported
                            in clinical studies as a result of infusion of the parenteral fluid were
                            water weight gain, edema, increase in BUN, and dilutional hyponatremia.       Asterixis was reported to have worsened in one patient during infusion
                            of this amino acid formulation.</paragraph><paragraph ID="INV-0172c6ed-b366-4f07-b145-571562845286">Reactions which may
                            occur because of the solution or the technique of administration include
                            febrile response, infection at the site of injection, venous thrombosis
                            or phlebitis extending from the site of injection, extravasation and
                            hypervolemia.</paragraph><paragraph ID="INV-98870a1e-fea8-481d-b158-c8fa54ad9fc4">Symptoms may result
                            from an excess or deficit of one or more of the ions present in the
                            solution; therefore, frequent monitoring of electrolyte levels is
                            essential.</paragraph><paragraph ID="INV-1641925f-614e-4ddb-a024-850be79a387f">Phosphorus
                            deficiency may lead to impaired tissue oxygenation and acute hemolytic
                            anemia. Relative to calcium, excessive phosphorus intake can precipitate
                            hypocalcemia with cramps, tetany and muscular hyperexcitability.</paragraph><paragraph ID="INV-868b31ce-db3d-4c28-ba02-c90ab3dc7c6f">If an adverse
                            reaction does occur, discontinue the infusion, evaluate the patient,
                            institute appropriate therapeutic countermeasures and save the remainder
                            of the fluid for examination if deemed necessary.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
<component>
<section ID="INV-40b6197f-1945-4414-9a75-fa0d6bd99530">
<id root="7DD2FBBA-57FA-F88C-0BA7-7A3225819AEF" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE SECTION" />
<title ID="INV-1ec102fc-2748-4c47-804d-39ba9dbc1ea4" mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
<text ID="INV-5f54a05a-6571-44d2-966f-0c38589355ae"><paragraph ID="INV-211f6b1f-0a2c-4596-bc2c-85ec5d7d98d0">In the event of a
                            fluid or solute overload during parenteral therapy, re-evaluate the
                            patient&#8217;s condition, and institute appropriate corrective
                        treatment.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
<component>
<section ID="INV-4a70a3ab-da2f-4786-a379-5c917bf5657e">
<id root="7E641D0A-7FEC-8AE0-46FF-CF2D39101F01" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE AND ADMINISTRATION SECTION" />
<title ID="INV-c4c274e2-daca-4813-b4aa-50b859ee4c12" mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text ID="INV-6133f570-c1fb-4028-92c6-9e2456030ae2"><paragraph ID="INV-78adea40-62df-4555-a138-f9e6e77405c7">The objective of
                            nutritional management of patients with liver disease is the provision
                            of sufficient amino acid and caloric support for protein synthesis
                            without exacerbating hepatic encephalopathy.</paragraph><paragraph ID="INV-978dfe6f-bc94-4691-b307-305bc7e20701">The total daily
                            dose of 8% Hepatasol<sup>&#174;</sup> (Amino Acid) Injection depends on daily
                            protein requirements and on the patient's metabolic and clinical
                            response. The determination of nitrogen balance and accurate daily body
                            weights, corrected for fluid balance, are probably the best means of
                            assessing individual protein requirements. Dosage should also be guided
                            by the patient&#8217;s fluid intake limits and glucose and nitrogen
                            tolerances, as well as by metabolic and clinical response.</paragraph><paragraph ID="INV-43ef8447-8c1d-450d-91d7-6caedc974ebc">The recommended
                            dosage is 80-120 grams of amino acids (12-18 grams of nitrogen) as 8%
                                Hepatasol<sup>&#174;</sup> (Amino Acid) Injection per day. Typically, 500
                            mL of 8% Hepatasol<sup>&#174;</sup> (Amino Acid) Injection appropriately
                            mixed with 500 mL of 50% dextrose supplemented with electrolytes and
                            vitamins is administered over an 8-12 hour period. This results in a
                            total daily fluid intake of approximately 2-3 liters. Patients with
                            fluid restrictions may only tolerate 1-2 liters. Although nitrogen
                            requirements may be higher in severely hypercatabolic or depleted
                            patients, provision of additional nitrogen may not be possible due to
                            fluid intake limits, nitrogen, or glucose intolerance.</paragraph></text>
<effectiveTime value="20060613" />
<component>
<section ID="INV-c71f0021-b165-4757-b6c7-8d7bf564cd57">
<id root="FBD9E53C-246B-3E57-828C-FF6FB84310DD" />
<title ID="INV-716f2b22-0822-4390-b0f7-f861d78db7d7" mediaType="text/x-hl7-title+xml">Pediatric Use:</title>
<text ID="INV-c6b9824d-4dc8-4da4-b92e-0b4a212d6235"><paragraph ID="INV-9e5d3d80-fa5c-4bdb-92f5-455ed7ba55b0">Use of 8%
                                        Hepatasol<sup>&#174;</sup> (Amino Acid) Injection in pediatric             patients is governed by the same considerations that affect the
                                    use of any amino acid solution in pediatrics. The amount
                                    administered is dosed on the basis of grams of amino acids/kg of
                                    body weight/day. Two to three g/kg of body weight for infants
                                    with adequate calories are generally sufficient to satisfy
                                    protein needs and promote positive nitrogen balance. Solutions
                                    administered by peripheral vein should not exceed twice normal
                                    serum osmolarity (718 m0smol/L).</paragraph><paragraph ID="INV-39a95b4e-906b-4984-b32b-1fd2e930b665">In many
                                    patients, provision of adequate calories in the form of
                                    hypertonic dextrose may require the administration of exogenous
                                    insulin to prevent hyperglycemia and glycosuria. To prevent
                                    rebound hypoglycemia, a solution containing 5% dextrose should
                                    be administered when hypertonic dextrose solutions are abruptly
                                    discontinued.</paragraph><paragraph ID="INV-97d14005-6cb1-4dc4-935f-3be339bc443d">Fat
                                    emulsion coadministration should be considered when prolonged
                                    (more than 5 days) parenteral nutrition is required in order to
                                    prevent essential fatty acid deficiency (E.F.A.D.). Serum lipids
                                    should be monitored for evidence of E.F.A.D. in patients
                                    maintained on fat free TPN. Caution should be exercised in
                                    administering fat emulsions to patients with severe liver
                                    damage.</paragraph><paragraph ID="INV-14ea71af-da8c-4272-b240-b0a08546b75a">Fat
                                    emulsion may obscure the presence of precipitate formation.</paragraph><paragraph ID="INV-fdde00c0-0f4b-4448-b524-af195df94e4f">The
                                    provision of sufficient intracellular electrolytes, principally
                                    potassium, magnesium, and phosphate, is required for optimum
                                    utilization of amino acids. Approximately 60-160 mEq of
                                    potassium, 10-30 mEq of magnesium, and 10-40 mmoles of phosphate
                                    per day appear necessary to achieve optimum metabolic response.
                                    In addition, sufficient quantities of the major extracellular
                                    electrolytes sodium, calcium, and chloride, must be given. In
                                    patients with hyperchloremic or other metabolic acidoses, sodium
                                    and potassium may be added as the acetate salts to provide
                                    bicarbonate precursor. The electrolyte content of 8%
                                        Hepatasol<sup>&#174;</sup> (Amino Acid) Injection must be
                                    considered when calculating daily electrolyte intake. Serum
                                    electrolytes, including magnesium and phosphorus, should be     monitored frequently.</paragraph><paragraph ID="INV-94b19b16-8c09-469d-b6ac-852439f575b4">Hypertonic
                                    mixtures of amino acids and dextrose may be safely administered
                                    by continuous infusion through a central venous catheter with                     the tip located in the superior vena cava. Initial infusion
                                    rates should be slow, and gradually increased to the recommended
                                    60-125 mL/hr. If administration rate should fall behind
                                    schedule, no attempt to "catch up" to planned intake should be
                                    made. In addition to meeting protein needs, the rate of
                                    administration, particularly during the first few days of
                                    therapy, is governed by the patient's glucose tolerance. Daily
                                    intake of amino acids and dextrose should be increased gradually
                                    to the maximum required dose as indicated by frequent
                                    determinations of glucose levels in blood and urine.</paragraph><paragraph ID="INV-0894e052-7785-47f9-931b-55ffc13e6130">For
                                    patients in whom the central venous route is not indicated and
                                    who can consume adequate calories enterally, 8%
                                    Hepatasol<sup>&#174;</sup> (Amino Acid) Injection may be administered
                                    by peripheral vein with or without parenteral carbohydrate
                                    calories. Such infusates can be prepared by dilution of 8%
                                        Hepatasol<sup>&#174;</sup> (Amino Acid) Injection with Sterile
                                    Water for Injection or 5%-10% dextrose to prepare isotonic or                    slightly hypertonic solutions for peripheral infusion. It is
                                    essential that peripheral infusion be accompanied by adequate
                                    caloric supplementation. In pediatric patients, the final             solution should not exceed twice normal serum osmolarity (718
                                    mOsmol/L).</paragraph><paragraph ID="INV-ab935d25-22c8-4d3f-b06e-e0f4143de6c2">Parenteral
                                    drug products should be inspected visually for particulate
                                    matter and discoloration prior to administration, whenever
                                    solution and container permit.</paragraph><paragraph ID="INV-fad2c232-3805-4422-833e-da58a46b727d">Care must
                                    be taken to avoid incompatible admixtures. Consult with
                                    pharmacist.</paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-c1e58736-f2b7-46b1-87f8-118ff651ed64">
<id root="AD267CDF-43B1-8B4B-EC75-53F789212047" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION" />
<title ID="INV-c5e0355a-97ee-4be7-af0d-1be0c5b61efa" mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text ID="INV-5c6a31f1-d37b-49d3-b46e-5b4564f55df4"><paragraph ID="INV-b3f52237-0ee9-472d-8378-fc2b935b4e00">8%
                            Hepatasol<sup>&#174;</sup> (Amino Acid) Injection is supplied sterile and
                            nonpyrogenic in glass containers packaged as follows:</paragraph><table frame="void"><col align="left" width="150pt" />
<col align="left" width="150pt" />
<col align="left" width="150pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle">2A6173 </td><td align="left" valign="middle"> 500 mL </td><td align="left" valign="middle"> NDC 0338-0497-03 </td></tr>
</tbody>
</table><paragraph ID="INV-0d046d92-c5f6-4330-8c2f-0d7203d27549">Exposure of
                            pharmaceutical products to heat should be minimized. Avoid excessive
                            heat. Protect from freezing. It is recommended the product be stored at
                            room temperature (25&#186;C/77&#186;F): brief exposure up to 40&#186;C/104&#186;F does not
                            adversely affect the product.</paragraph><paragraph ID="INV-41fcb6f2-0434-403f-8b7f-38d653fc16a2">Protect from light
                            until use.</paragraph><paragraph ID="INV-2345a930-3e8d-4cce-a0f2-cb3d9fbcd747"><content styleCode="bold">Caution:</content> Federal (USA) law prohibits
                            dispensing without prescription.</paragraph><table border="1" frame="border"><col align="left" width="150pt" />
<tbody valign="top">
<tr valign="top"><td align="left" styleCode="Botrule Lrule Rrule" valign="middle">Bar Code Placement </td></tr>
</tbody>
</table><paragraph ID="INV-87146eb5-20ae-44fe-a8d7-85e7244af70b">071905013</paragraph><paragraph ID="INV-28d634af-0ec4-48d6-819d-5d9c92d44638"><content styleCode="bold">Baxter Healthcare Corporation</content></paragraph><paragraph ID="INV-6d410add-1b49-4789-8ea2-1940cb52b92f">Clintec Nutrition
                            Division</paragraph><paragraph ID="INV-ac7c4801-32dc-4d26-aca7-cdce7c8535e3">Deerfield, IL 60015
                            USA</paragraph><paragraph ID="INV-c878f18a-b3e5-4505-bee9-1bbe927127ab">Printed in USA</paragraph><paragraph ID="INV-9ddbc885-7c31-4ae8-b331-8f45119acaba">Copyright 1997,
                            1999, 2000, Baxter Healthcare Corporation. All rights reserved.</paragraph><paragraph ID="INV-8026e8a5-6fee-4d5d-ac33-588eb45e6b18"><content styleCode="bold">07-19-05-013</content></paragraph></text>
<effectiveTime value="20060613" />
</section>
</component>
</structuredBody>
</component>
</document>
